Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis

Lakatos, G. Firneisz, Borcsiczky, Zalatnai, Selmeci, Szalay

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Dipeptidyl peptidase IV (DPP IV) is a cell surface ectoenzyme widely distributed in the rat body, present on the epithelial cells of the brush border membranes (e.g. bile canaliculi) and on the surface of reactive lymphocytes and fibroblasts. DPP IV has been implicated in hepatocyte-extracellular matrix interactions, fibroblast activation and proliferation and in T-cell activation. Aberrant DPP IV expression was found in human liver cirrhosis, and elevated serum DPP IV activity was reported in patients with primary biliary cirrhosis and chronic hepatitis C virus infection. The aim of the study was to examine serum DPP IV activity in experimental liver cirrhosis. Methods: Liver cirrhosis was induced by administering diethyl-nitrosamine, phenobarbital and CCl4 in Fischer-344 male rats (n = 22). Phenobarbital-treated (n = 9) and nontreated (n=9) male rats were used as controls. Serum DPP IV activity was measured using a microplate-based continuous-monitoring assay. Recombinant rat DPP IV was used as standard and Gly-Pro-PNA was used as substrate. Enzyme activity was given in nmol mL-1 min-1 (UL-1). Results: Significantly higher DPP IV activity was found in the sera of rats with experimental liver cirrhosis (39·2 ± 3·7; mean ± SD) compared to phenobarbital-treated (11 ± 4, P <0·000002) and nontreated (10·9 ± 0·9, P <0·000002) rats. There was a positive correlation between DPP IV activity and concentrations of aspartate aminotransferase (r= 0·73, P=0·0001) and alanine aminotransferase (r= 0·69, P= 0·0004). Conclusions. The significantly higher serum DPP IV activity found in experimental liver cirrhosis is in concordance with human observations. The elevation was probably not due to the enzyme induction effect of phenobarbital. In this experimental model, serum DPP IV seems to be an indicator for chronic liver injury.

Original languageEnglish
Pages (from-to)793-797
Number of pages5
JournalEuropean Journal of Clinical Investigation
Volume30
Issue number9
DOIs
Publication statusPublished - 2000

Fingerprint

Experimental Liver Cirrhosis
Dipeptidyl Peptidase 4
Liver
Serum
Rats
Phenobarbital
Fibroblasts
Liver Cirrhosis
glycylproline
Chemical activation
Bile Canaliculi
Nitrosamines
Enzyme Induction
T-cells
Lymphocytes
Biliary Liver Cirrhosis
Enzyme activity
Chronic Hepatitis C
Virus Diseases
Brushes

Keywords

  • CD26
  • DPP IV
  • Experimental model
  • Fibrogenesis
  • Liver cirrhosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. / Lakatos, ; Firneisz, G.; Borcsiczky; Zalatnai; Selmeci; Szalay.

In: European Journal of Clinical Investigation, Vol. 30, No. 9, 2000, p. 793-797.

Research output: Contribution to journalArticle

@article{fd8cba4fd79f4697a0bc4a264f7b0b38,
title = "Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis",
abstract = "Background: Dipeptidyl peptidase IV (DPP IV) is a cell surface ectoenzyme widely distributed in the rat body, present on the epithelial cells of the brush border membranes (e.g. bile canaliculi) and on the surface of reactive lymphocytes and fibroblasts. DPP IV has been implicated in hepatocyte-extracellular matrix interactions, fibroblast activation and proliferation and in T-cell activation. Aberrant DPP IV expression was found in human liver cirrhosis, and elevated serum DPP IV activity was reported in patients with primary biliary cirrhosis and chronic hepatitis C virus infection. The aim of the study was to examine serum DPP IV activity in experimental liver cirrhosis. Methods: Liver cirrhosis was induced by administering diethyl-nitrosamine, phenobarbital and CCl4 in Fischer-344 male rats (n = 22). Phenobarbital-treated (n = 9) and nontreated (n=9) male rats were used as controls. Serum DPP IV activity was measured using a microplate-based continuous-monitoring assay. Recombinant rat DPP IV was used as standard and Gly-Pro-PNA was used as substrate. Enzyme activity was given in nmol mL-1 min-1 (UL-1). Results: Significantly higher DPP IV activity was found in the sera of rats with experimental liver cirrhosis (39·2 ± 3·7; mean ± SD) compared to phenobarbital-treated (11 ± 4, P <0·000002) and nontreated (10·9 ± 0·9, P <0·000002) rats. There was a positive correlation between DPP IV activity and concentrations of aspartate aminotransferase (r= 0·73, P=0·0001) and alanine aminotransferase (r= 0·69, P= 0·0004). Conclusions. The significantly higher serum DPP IV activity found in experimental liver cirrhosis is in concordance with human observations. The elevation was probably not due to the enzyme induction effect of phenobarbital. In this experimental model, serum DPP IV seems to be an indicator for chronic liver injury.",
keywords = "CD26, DPP IV, Experimental model, Fibrogenesis, Liver cirrhosis",
author = "Lakatos and G. Firneisz and Borcsiczky and Zalatnai and Selmeci and Szalay",
year = "2000",
doi = "10.1046/j.1365-2362.2000.00698.x",
language = "English",
volume = "30",
pages = "793--797",
journal = "European Journal of Clinical Investigation",
issn = "0014-2972",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis

AU - Lakatos,

AU - Firneisz, G.

AU - Borcsiczky,

AU - Zalatnai,

AU - Selmeci,

AU - Szalay,

PY - 2000

Y1 - 2000

N2 - Background: Dipeptidyl peptidase IV (DPP IV) is a cell surface ectoenzyme widely distributed in the rat body, present on the epithelial cells of the brush border membranes (e.g. bile canaliculi) and on the surface of reactive lymphocytes and fibroblasts. DPP IV has been implicated in hepatocyte-extracellular matrix interactions, fibroblast activation and proliferation and in T-cell activation. Aberrant DPP IV expression was found in human liver cirrhosis, and elevated serum DPP IV activity was reported in patients with primary biliary cirrhosis and chronic hepatitis C virus infection. The aim of the study was to examine serum DPP IV activity in experimental liver cirrhosis. Methods: Liver cirrhosis was induced by administering diethyl-nitrosamine, phenobarbital and CCl4 in Fischer-344 male rats (n = 22). Phenobarbital-treated (n = 9) and nontreated (n=9) male rats were used as controls. Serum DPP IV activity was measured using a microplate-based continuous-monitoring assay. Recombinant rat DPP IV was used as standard and Gly-Pro-PNA was used as substrate. Enzyme activity was given in nmol mL-1 min-1 (UL-1). Results: Significantly higher DPP IV activity was found in the sera of rats with experimental liver cirrhosis (39·2 ± 3·7; mean ± SD) compared to phenobarbital-treated (11 ± 4, P <0·000002) and nontreated (10·9 ± 0·9, P <0·000002) rats. There was a positive correlation between DPP IV activity and concentrations of aspartate aminotransferase (r= 0·73, P=0·0001) and alanine aminotransferase (r= 0·69, P= 0·0004). Conclusions. The significantly higher serum DPP IV activity found in experimental liver cirrhosis is in concordance with human observations. The elevation was probably not due to the enzyme induction effect of phenobarbital. In this experimental model, serum DPP IV seems to be an indicator for chronic liver injury.

AB - Background: Dipeptidyl peptidase IV (DPP IV) is a cell surface ectoenzyme widely distributed in the rat body, present on the epithelial cells of the brush border membranes (e.g. bile canaliculi) and on the surface of reactive lymphocytes and fibroblasts. DPP IV has been implicated in hepatocyte-extracellular matrix interactions, fibroblast activation and proliferation and in T-cell activation. Aberrant DPP IV expression was found in human liver cirrhosis, and elevated serum DPP IV activity was reported in patients with primary biliary cirrhosis and chronic hepatitis C virus infection. The aim of the study was to examine serum DPP IV activity in experimental liver cirrhosis. Methods: Liver cirrhosis was induced by administering diethyl-nitrosamine, phenobarbital and CCl4 in Fischer-344 male rats (n = 22). Phenobarbital-treated (n = 9) and nontreated (n=9) male rats were used as controls. Serum DPP IV activity was measured using a microplate-based continuous-monitoring assay. Recombinant rat DPP IV was used as standard and Gly-Pro-PNA was used as substrate. Enzyme activity was given in nmol mL-1 min-1 (UL-1). Results: Significantly higher DPP IV activity was found in the sera of rats with experimental liver cirrhosis (39·2 ± 3·7; mean ± SD) compared to phenobarbital-treated (11 ± 4, P <0·000002) and nontreated (10·9 ± 0·9, P <0·000002) rats. There was a positive correlation between DPP IV activity and concentrations of aspartate aminotransferase (r= 0·73, P=0·0001) and alanine aminotransferase (r= 0·69, P= 0·0004). Conclusions. The significantly higher serum DPP IV activity found in experimental liver cirrhosis is in concordance with human observations. The elevation was probably not due to the enzyme induction effect of phenobarbital. In this experimental model, serum DPP IV seems to be an indicator for chronic liver injury.

KW - CD26

KW - DPP IV

KW - Experimental model

KW - Fibrogenesis

KW - Liver cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=0033811058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033811058&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2362.2000.00698.x

DO - 10.1046/j.1365-2362.2000.00698.x

M3 - Article

VL - 30

SP - 793

EP - 797

JO - European Journal of Clinical Investigation

JF - European Journal of Clinical Investigation

SN - 0014-2972

IS - 9

ER -